Louisiana Medicaid
Diabetes – Hypoglycemics – Incretin Mimetics / Enhancers

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request:

- Prior authorization for non-preferred incretin mimetic/enhancers (except GLP-1 agonists); **AND**
- Clinical authorization for GLP-1 agonists.

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available HERE.

Approval Criteria for Initiation and Continuation of Therapy (Except GLP-1 Agonists)

- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; **AND**
- If the request is for a DPP-4, the prescriber attests that the requested DPP-4 agent will not be used concurrently with a GLP-1 agent; **AND**
- If the request is for a DPP-4, the recipient has had a failure to respond or an intolerance to one preferred DPP-4; **OR**
- If the request is for a DPP-4 / metformin combination, the recipient has had a failure to respond or an intolerance to one preferred DPP-4 / metformin combination; **OR**
- If the request is for DPP-4 / metformin extended-release combination, the recipient has had a failure to respond or an intolerance to one preferred DPP-4 / metformin extended release combination; **OR**
- If the request is for a DPP-4 / thiazolidinedione combination, the recipient has had a failure to respond or an intolerance to one preferred alternative in this therapeutic class; **OR**
- If the request is for a non-preferred amylin analog:
    - The prescriber **states on the request** that the recipient has failed to achieve glycemic control despite optimal insulin therapy; **AND**
    - The recipient has had a failure to respond or an intolerance to one preferred amylin analog (if available); **OR**
- **ONE** of the following is required:
    - The recipient has a *documented contraindication* to all of the preferred products that are appropriate to use for the condition being treated; **OR**
    - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
    - The recipient is established on the medication with positive clinical outcomes**.**

Duration of approval for initiation and continuation of therapy: 12 months

---

GLP-1 Agonists

Initial Approval Criteria

- The recipient meets the minimum age requirement (see POS Edits); **AND**
- The recipient has a diagnosis of type 2 diabetes mellitus; **AND**
- Documentation is provided confirming a history a **hemoglobin A1C (A1C) ≥ 6.5%, with associated date.** *Note: Established therapy without the above-referenced history of an A1C ≥ 6.5% is not accepted for initial approval*; **AND**

- ~~**ONE** of the following: (A1C test results and date must be **stated on the request**)~~
- ~~The recipient has a hemoglobin A1C (A1C) ≥ 6.5% obtained within the previous 6-month period; **OR**~~
- ~~**ALL** of the following:~~
- ~~The recipient has an A1C < 6.5% obtained within the previous 6-month period; **AND**~~
- ~~The recipient has a history of an A1C ≥ 6.5%; **AND**~~
- By submitting the authorization request, the prescriber attests that the requested GLP-1 agent will not be ~~use~~used concurrently with a DPP-4 agent; **AND**
- If request is for a non-preferred GLP-1 agent – **ONE** of the following is required:
    - The recipient has had a *treatment failure* with at least one preferred GLP-1 product; **OR**
    - The recipient has had an *intolerable side effect* to at least one preferred GLP-1 product; **OR**
    - The recipient has *documented contraindication(s)* to all of the preferred GLP-1 products that are appropriate to use for the condition being treated; **OR**
    - There is *no preferred product that is appropriate* to use for the condition being treated**.**

Subsequent Approval Criteria

Note: Subsequent approval criteria should be used only if the recipient has previously obtained an initial approval using the criteria listed above.

- The prescriber states on the request that the recipient is established on the medication with evidence of a positive response to therapy.

Duration of approval for initial or subsequent requests: 6~~12~~ months

References

American Diabetes Association Professional Practice Committee; Introduction and Methodology: *Standards of Care in Diabetes—2024*. *Diabetes Care* 1 January 2024; 47 (Supplement_1): S1–S4. https://doi.org/10.2337/dc24-SINT

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; https://www.clinicalkey.com/pharmacology/

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill; https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861

Dulaglutide (Trulicity) [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2022. https://uspl.lilly.com/trulicity/trulicity.html#pi

Exenatide (Bydureon Bcise) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; May 2023. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/df5ddbd6-546b-43da-b794-56f711189aba/df5ddbd6-546b-43da-b794-56f711189aba_viewable_rendition__v.pdf

Exenatide (Byetta) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; December 2022. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/ce8afab9-2b45-436d-957c-a73978d09e93/ce8afab9-2b45-436d-957c-a73978d09e93_viewable_rendition__v.pdf

Liraglutide (Victoza) [package insert]. Plainsboro, NJ: Novo Nordisk Inc; July 2023. https://www.novo-pi.com/victoza.pdf

Semaglutide (Ozempic) [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2023. https://www.ozempic.com/prescribing-information.html

Semaglutide (Rybelsus) [package insert]. Plainsboro, NJ: Novo Nordisk Inc; January 2024. https://www.novo-pi.com/rybelsus.pdf

Tirzepatide (Mounjaro) [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2024. https://uspl.lilly.com/mounjaro/mounjaro.html#pi

Revision / Date	**Implementation Date**
Single PDL Implementation	May 2019
Formatting changes; removed POS wording / April 2021	July 2021
Diagnosis requirement policy clarification / August 2023	October 2023
Added age requirement criterion, formatting changes / February 2024	April 2024
Added clinical authorization requirement for GLP-1 agonists, updated references / August 2024	November 2024
Clarification of A1C criterion, addition of TD criterion / December 2024	January 2025
Simplified A1C criterion for clarification, modified duration of approval / March 2025	August 2025